Mitochondrial dysfunction in CD4+lymphocytes from stavudine-treated HIV patients

Mitochondrion

Volumn 10, Issue 5, 2010, Pages 534-539

  Einsiedel, Lloyd ^a,b,c   Cherry, Catherine L ^a,b,c   Sheeran, Freya L ^b,d   Friedhuber, Anna ^e   Wesselingh, Steve L ^a,b,c   Pepe, Salvatore ^b,d  

^a MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

CD4+; HIV; Lymphocyte; Mitochondria; Nucleoside analogue reverse transcriptase inhibitors; Oxygen consumption

Indexed keywords

CITRATE SYNTHASE; MITOCHONDRIAL DNA; STAVUDINE;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA CONTENT; ELECTRON MICROSCOPY; ENZYME ACTIVITY; GENE DOSAGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MITOCHONDRIAL RESPIRATION; MITOCHONDRIAL VOLUME; MITOCHONDRION; OXYGEN CONSUMPTION; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RESPIRATORY CHAIN; TREATMENT DURATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CITRATE (SI)-SYNTHASE; DNA, MITOCHONDRIAL; HIV INFECTIONS; HUMANS; MIDDLE AGED; MITOCHONDRIA; MITOCHONDRIAL DISEASES; OXYGEN CONSUMPTION; STAVUDINE;

EID: 77955416035     PISSN: 15677249     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mito.2010.05.010     Document Type: Article

References (28)

1. Anderson S., Bankier A., Barrell B., de Bruijin M., Coulson A., Drouin J., Eperon I., Nierlich D., Roe B., Sanger F., Schreier P., Smith A., Staden R., Moyle G., Young I. Sequence and organization of the human mitochondrial genome. Nature 1981, 290:457-465.
2. Cherry C.L., Lal L., Thompson K.A., McLean C.A., Ross L.L., Hernandez J., Wesselingh S.L., McComsey G. Increased adipocyte apoptosis in lipoatrophy improves within 48weeks of switching patient therapy from Stavudine to abacavir or zidovudine. J. Acquir. Immune Defic. Syndr. 2005, 38:263-267.
3. Cherry C.L., Nolan D., James I.R., McKinnon E.J., Mallal S.A., Gahan M.E., Lal L., McArthur J.C., Wesselingh S.L. Tissue-specific associations between mitochondrial DNA levels and current treatment status in HIV-infected individuals. J.Acquir. Immune Defic. Syndr. 2006, 42:435-440.
4. Chiappini F., Teicher E., Saffroy R., Pham P., Falissard B., Barrier A., Chevalier S., Debuire B., Vittecoq D., Lemoine A. Prospective evaluation of blood concentration of mitochondrial DNA as a marker of toxicity in 157 consecutively recruited untreated or HAART-treated HIV positive patients. Lab. Inv. 2004, 84:908-914.
5. Cossarizza A. Tests for mitochondrial function and DNA: potentials and pitfalls. Curr. Opin Infect. Dis. 2003, 16:5-10.
6. Cossarizza A., Moyle G. Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS 2004, 18:137-151.
7. Cote H., Brumme Z., Craib K., Alexander C., Wynhoeven B., Ting L., Wong H., Harris M., Harrigan P., O'Shaughnessy M., Montaner J. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV infected patients. New Engl. J. Med. 2002, 346:811-820.
8. De Mendoza C., DeRonde A., Smolders K., Blanco F., Garcia-Benayas T., De Baar M., Fernandez-Casas P., Gonzalez-Lahoz J., Soriano V. Changes in mitochondrial DNA copy number in blood cells from HIV-infected patients undergoing antiretroviral therapy. AIDS. Res Hum Retrov. 2004, 20:271-273.
9. DiMauro S., Tay S., Mancuso M. Mitochondrial encephalomyopathies, diagnostic approach. Ann. NY. Acad. Sci. 2004, 1011:217-231.
10. Gahan M., Miller F., Lewin S., Cherry C., Hoy J., Mijch A., Rosenfeldt F., Wesselingh S. Quantification of mitochondrial DNA in peripheral blood mononuclear cells and subcutaneous fat using real time polymerase chain reaction. J.Clin.Virol. 2001, 22:241-247.
11. Halestrap A.P. The regulation of the matrix volume of mammalian mitochondria in vivo and in vitro and its role in the control of mitochondrial metabolism. Biochim Biophys 1989, 973:355-382.
12. Hood D. Contractile activity-induced mitochondrial biogenesis in skeletal muscle. J. Appl. Physiol. 2001, 90:1137-1157.
13. Mallewa J.E., Wilkins E., Vilar J., Mallewa M., Doran D., Back D., Pirmohamed M. HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options. J. Antimicrob. Chemother. 2008, 62:648-660.
14. Mallon P.W., Unemori P., Sedwell R., Morey A., Rafferty M., Williams K., Chisholm D., Samaras K., Emery S., Kelleher A., Cooper D.A., Carr A. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J. Infect. Dis. 2005, 191:1686-1696. SAMA investigators.
15. Martin J., Brown C., Matthews-Davis N. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob. Agents Chemother. 1994, 38:2743-2749.
16. Miro O., Lopez S., Pedrol E., Rodriguez-Santiago B. Mitochondrial DNA depletion and respiratory chain enzyme deficiencies are present in peripheral blood mononuclear cells of HIV infected patients with HAART related lipodystrophy. Antivir. Ther. 2003, 8:333-338.
17. Miro O., Lopez S., Rodriguez de la Concepcion M., Martinez E., Pedrol E., Garrabou G., Giralt M., Cardellach F., Garell J., Villarota F., Casedemont J. Upregulatory mechanisms compensate for mitochondrial DNA depletion in asymptomatic individuals receiving stavudine and didanosine. J. Acquir. Immune Defic. Syndr. 2004, 37:1550-1555.
18. Montaner J., Cote H., Harris M., Hogg R., Yip B., Chan J., Harrigan R., O'Shaughnessy M. Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV infected patients taking antiretroviral therapy. J. Acquir. Immune. Defic. Syndr. 2003, 34:S85-90.
19. Moraes C.T. What regulates mitochondrial DNA copy number in animal cells?. Trends Genet. 2001, 17:199-205.
20. Nolan D., Hammond E., James J., McKinnon E., Mallal S. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir. Ther. 2003, 8:617-626.
21. Palella K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New. Engl. J. Med. 1998, 338:853-860.
22. Petit C., Mathez D., Barthélémy C., Leste-Lassere T. Quantification of blood mitochondrial DNA for the monitoring of antiretroviral drug induced DNA depletion. J. Acquir. Immune Defic. Syndr. 2003, 33:461-469.
23. SAHIV, Southern African HIV Clinicians Society, 2005. Guidelines for Antiretroviral Therapy in Adults. Southern African J. HIV Med. March, 18-31.
24. Vittecoq D., Jardel C., Barthélémy C., Escaut L., Cheminot N., Chapin S., Sternberg D., Maisonobe T., Lombès A. Mitochondrial damage associated with long-term antiretroviral treatment: associated alteration or causal disorder?. J. Acquir. Immune. Defic. Syndr. 2002, 31:299-308.
25. Waters L., Nelson M. Long-term complications of antiretroviral therapy: lipoatrophy. Int. J. Clin. Pract. 2007, 61:999-1014.
26. Weibel E.R. Stereological Methods 1979, vol. 1. Academic Press, London.
27. White A. Mitochondrial toxicity and HIV therapy. Sex. Transm. Infect. 2001, 77:158-173.
28. Wierzbicki A.S., Purdon S.D., Hardman T.C., Kulasegaram R., Peters B.S. HIV lipodystrophy and its metabolic consequences: implications for clinical practice. Curr. Med. Res. Opin. 2008, 24:609-624.